Acorda Therapeutics, Inc. – NASDAQ:ACOR
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Acorda Therapeutics stock price monthly change
-88.90%
month
Acorda Therapeutics stock price quarterly change
-88.59%
quarter
Acorda Therapeutics stock price yearly change
+202.38%
year
Acorda Therapeutics key metrics
Market Cap | 821.02K |
Enterprise value | 146.21M |
P/E | -0.16 |
EV/Sales | 0.84 |
EV/EBITDA | -295.39 |
Price/Sales | 0.06 |
Price/Book | 0.11 |
PEG ratio | N/A |
EPS | -262.58 |
Revenue | 115.66M |
EBITDA | 346K |
Income | -263.42M |
Revenue Q/Q | -8.84% |
Revenue Y/Y | -2.22% |
Profit margin | -79.65% |
Oper. margin | -62.18% |
Gross margin | 73.8% |
EBIT margin | -62.18% |
EBITDA margin | 0.3% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAcorda Therapeutics stock price history
Acorda Therapeutics stock forecast
Acorda Therapeutics financial statements
| Jun 2023 | 29.67M | -9.38M | -31.61% |
|---|---|---|---|
| Sep 2023 | 27.71M | -8.88M | -32.07% |
| Dec 2023 | 37.98M | -217.76M | -573.28% |
| Mar 2024 | 20.28M | -27.39M | -135.02% |
| 2025 | 163.09M | -42.47M | -26.04% |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 364696000 | 296.82M | 81.39% |
|---|---|---|---|
| Sep 2023 | 366344000 | 307.38M | 83.91% |
| Dec 2023 | 117745000 | 275.70M | 234.15% |
| Mar 2024 | 81575000 | 267.34M | 327.73% |
| Jun 2023 | -11.55M | 0 | 0 |
|---|---|---|---|
| Sep 2023 | 7.60M | -220K | -6.88M |
| Dec 2023 | -3.01M | -44K | 6.88M |
| Mar 2024 | -20.18M | 0 | 0 |
Acorda Therapeutics alternative data
| Aug 2023 | 111 |
|---|---|
| Sep 2023 | 111 |
| Oct 2023 | 111 |
| Nov 2023 | 111 |
| Dec 2023 | 111 |
| Jan 2024 | 111 |
| Feb 2024 | 111 |
| Mar 2024 | 111 |
| Apr 2024 | 111 |
| May 2024 | 102 |
| Jun 2024 | 102 |
| Jul 2024 | 102 |
Acorda Therapeutics other data
87.90%
+9.10%
of ACOR is owned by hedge funds
11.64M
+3.27M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 20156 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | COHEN RON director, officer.. | Common Stock | 10,000 | $0.65 | $6,500 | ||
Purchase | COHEN RON director, officer.. | Common Stock | 10,156 | $0.6 | $6,094 | ||
Sale | COHEN RON director, officer.. | Common Stock | 2,289 | $1.7 | $3,894 | ||
Sale | WASMAN JANE officer: President, Intl and GC | Common Stock | 2,227 | $1.6 | $3,552 | ||
Sale | LAWRENCE DAVID officer: Chief, Bus. Ops & PAO | Common Stock | 1,176 | $1.6 | $1,880 | ||
Sale | SABELLA LAUREN M officer: Chief Co.. | Common Stock | 1,513 | $1.6 | $2,421 | ||
Sale | COHEN RON director, officer.. | Common Stock | 4,699 | $1.6 | $7,504 | ||
Sale | LAWRENCE DAVID officer: Chief, Bus. Ops & PAO | Common Stock | 761 | $13.18 | $10,028 | ||
Sale | SABELLA LAUREN M officer: Chief Co.. | Common Stock | 761 | $13.18 | $10,028 | ||
Sale | SCOPIA CAPITAL MANAGEMENT LP 10 percent owner | Common Stock | 7,000 | $16.01 | $112,042 |
| Patent |
|---|
Application Filling date: 26 Oct 2021 Issue date: 10 Feb 2022 |
Application Filling date: 13 Jul 2021 Issue date: 4 Nov 2021 |
Grant Filling date: 17 Jul 2017 Issue date: 12 Oct 2021 |
Grant Filling date: 1 Jul 2019 Issue date: 5 Oct 2021 |
Application Filling date: 4 May 2021 Issue date: 19 Aug 2021 |
Grant Utility: Methods for detecting cardiac damage Filling date: 20 Mar 2019 Issue date: 27 Jul 2021 |
Application Filling date: 16 Mar 2021 Issue date: 8 Jul 2021 |
Grant Utility: Water-soluble acetaminophen analogs Filling date: 9 Sep 2019 Issue date: 1 Jun 2021 |
Application Filling date: 4 Dec 2020 Issue date: 25 Mar 2021 |
Application Filling date: 18 May 2020 Issue date: 4 Mar 2021 |
| Quarter | Transcript |
|---|---|
| Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 11 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 10 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Ron Cohen M.D. (1956) Founder, Chief Executive Officer, Pres & Director | $1,500,000 |
| Dr. Burkhard Blank M.D. (1955) Consultant | $860,590 |
| Ms. Lauren M. Sabella (1961) Chief Operating Officer | $758,610 |
-
When is Acorda Therapeutics's next earnings date?
Unfortunately, Acorda Therapeutics's (ACOR) next earnings date is currently unknown.
-
Does Acorda Therapeutics pay dividends?
No, Acorda Therapeutics does not pay dividends.
-
How much money does Acorda Therapeutics make?
Acorda Therapeutics has a market capitalization of 821.02K and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 0.79% to 117.63M US dollars.
-
What is Acorda Therapeutics's stock symbol?
Acorda Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ACOR".
-
What is Acorda Therapeutics's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Acorda Therapeutics?
Shares of Acorda Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Acorda Therapeutics's key executives?
Acorda Therapeutics's management team includes the following people:
- Dr. Ron Cohen M.D. Founder, Chief Executive Officer, Pres & Director(age: 69, pay: $1,500,000)
- Dr. Burkhard Blank M.D. Consultant(age: 70, pay: $860,590)
- Ms. Lauren M. Sabella Chief Operating Officer(age: 64, pay: $758,610)
-
Is Acorda Therapeutics founder-led company?
Yes, Acorda Therapeutics is a company led by its founder Dr. Ron Cohen M.D..
-
How many employees does Acorda Therapeutics have?
As Jul 2024, Acorda Therapeutics employs 102 workers, which is 8% less then previous quarter.
-
When Acorda Therapeutics went public?
Acorda Therapeutics, Inc. is publicly traded company for more then 19 years since IPO on 10 Feb 2006.
-
What is Acorda Therapeutics's official website?
The official website for Acorda Therapeutics is acorda.com.
-
Where are Acorda Therapeutics's headquarters?
Acorda Therapeutics is headquartered at 420 Saw Mill River Road, Ardsley, NY.
-
How can i contact Acorda Therapeutics?
Acorda Therapeutics's mailing address is 420 Saw Mill River Road, Ardsley, NY and company can be reached via phone at +91 43474300.
Acorda Therapeutics company profile:
Acorda Therapeutics, Inc.
acorda.comExchange:
NASDAQ
Full time employees:
102
Industry:
Drug Manufacturers - Specialty & Generic
Sector:
Healthcare
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
420 Saw Mill River Road
Ardsley, NY 10502
Ardsley, NY 10502
CIK: 0001008848
ISIN: US00484M7002
CUSIP: 00484M106
